HIM
ORGO icon

Hillsdale Investment Management’s Organogenesis Holdings ORGO Stock Holding History

Hillsdale Investment Management’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-61,400
Closed -$1.02M – 618
2021
Q2 		$1.02M Sell
61,400
-5,000
-8% -$93.2K 0.08% 253
2021
Q1 		$1.21M Buy
+66,400
New +$900K 0.1% 204

Other funds holding ORGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
NMIMC
Northwestern Mutual Investment Management Company Milwaukee, Wisconsin $6.6B AUM 19.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Hillsdale Investment Management's ORGO Position: Q3 2021 in Review

Hillsdale Investment Management sold out of Organogenesis Holdings (ORGO) in Q3 2021, closing a stake of 61,400 shares — an estimated $1.02M sold.

Hillsdale Investment Management first reported a position in ORGO in Q1 2021 and held it in 2 quarters. The position peaked at $1.21M in Q1 2021. 153 funds tracked by Wall St. Rank hold ORGO as of Q3 2021.

  • Hillsdale Investment Management reported no remaining Organogenesis Holdings position as of Q3 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 61,400 Organogenesis Holdings shares in Q3 2021, an estimated $1.02M.
  • Hillsdale Investment Management first reported a position in Organogenesis Holdings in Q1 2021 and held it in 2 quarters.
  • Hillsdale Investment Management's Organogenesis Holdings position peaked at $1.21M in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q3 2021.

Based on Hillsdale Investment Management's 13F filing for Q3 2021, filed 21 Oct 2021.